Sponsors of brand respiratory drugs are expected to remove hydrofluorocarbons as the device propellant, which could leave generic companies scrambling absent help from the US Food and Drug Administration.
Janet Vaughn, Teva VP of North American generic regulatory affairs, said the FDA could use generic drug user fee...